Opus Genetics (IRD) director awarded 24,367 restricted stock units, now holds 343,022 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Rodgers Richard J reported acquisition or exercise transactions in this Form 4 filing.

Opus Genetics, Inc. director Richard J. Rodgers received an equity grant in the form of restricted stock units covering 24,367 shares of common stock. The award was granted at no cash cost per share and is part of his director compensation.

The restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day before Opus Genetics’ next annual stockholders’ meeting, provided he continues to serve through the vesting date. After this grant, he directly holds 343,022 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rodgers Richard J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,367	$0.00	--

Holdings After Transaction: Common Stock — 343,022 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 24,367 shares Transaction price: $0.00 per share Post-grant holdings: 343,022 shares +1 more

4 metrics

RSU grant size 24,367 shares Restricted stock unit award to director Rodgers

Transaction price $0.00 per share Reported grant price for restricted stock units

Post-grant holdings 343,022 shares Total common stock directly held after the award

Vesting schedule Earlier of 1 year or pre-next annual meeting Service-based vesting condition for RSUs

Key Terms

restricted stock units, vesting, annual meeting of stockholders, continuing service, +1 more

5 terms

restricted stock units financial

"Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"which vest upon the earlier of the one (1) year anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date"

continuing service financial

"subject to the Reporting Person's continuing service through the vesting date"

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

04/22/2026 - 04:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodgers Richard J

(Last)

(First)

(Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM

NORTH CAROLINA

27713

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/20/2026		A		24,367⁽¹⁾	A	$0	343,022	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

	/s/ Amy Rabourn, by Power of Attorney	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Opus Genetics (IRD) director Richard J. Rodgers report on this Form 4?

Richard J. Rodgers reported receiving a grant of restricted stock units for 24,367 shares of Opus Genetics common stock. The grant was recorded as an acquisition with no cash price per share, increasing his directly held position to 343,022 shares after the award.

How many Opus Genetics (IRD) shares were granted to Richard J. Rodgers?

He received an award covering 24,367 shares of Opus Genetics common stock in the form of restricted stock units. These units are part of his equity compensation as a director and will convert into shares when the vesting conditions described in the Form 4 are satisfied.

What are the vesting terms of Richard J. Rodgers’ restricted stock units at Opus Genetics (IRD)?

The restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day before Opus Genetics’ next annual meeting of stockholders. Vesting is conditioned on his continued service as of the vesting date, as described in the Form 4 footnote.

Did Richard J. Rodgers pay a purchase price for the Opus Genetics (IRD) shares granted?

No cash purchase price was reported for this grant. The Form 4 shows a transaction price per share of 0.0000, indicating these restricted stock units were awarded as compensation rather than bought in an open-market transaction or private purchase.

How many Opus Genetics (IRD) shares does Richard J. Rodgers hold after this grant?

Following the grant, Richard J. Rodgers directly holds 343,022 shares of Opus Genetics common stock. This total includes the newly awarded restricted stock units, which will vest according to the service-based schedule outlined in the Form 4’s footnote.

Is Richard J. Rodgers’ Opus Genetics (IRD) transaction a buy or a compensation grant?

The Form 4 classifies the transaction under code A as a grant, award, or other acquisition rather than an open-market purchase. It represents an equity compensation award of restricted stock units, not a discretionary share buy on the stock market.